Form 4: Amgen SVP Nancy Grygiel Reports Stock Transactions

Amgen SVP and CCO Nancy A. Grygiel reported the sale of 1,237 shares and the withholding of 242 shares for tax obligations.

Summary

• Nancy A. Grygiel, SVP & CCO of Amgen Inc., executed transactions involving common stock on May 2, 2026, and May 4, 2026.
• A total of 242 shares were withheld by the company to satisfy tax withholding obligations related to equity vesting at a price of $329.82 per share.
• A total of 1,237 shares were sold on May 4, 2026, at an average price of $323.7272 per share.
• Following these transactions, the reporting person maintains direct ownership of 7,009 shares and indirect ownership of 106.1864 shares via a 401(k) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions appear to be routine administrative actions related to tax obligations and standard equity management.

Positives

• The reporting person maintains a significant ongoing equity stake of 7,009 shares in the company.

Negatives

• The filing reflects a reduction in the direct beneficial ownership of the reporting person.

Risks

• None identified in this specific Form 4 filing.

Future Outlook

No forward-looking guidance provided in this document.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as tax withholdings and planned sales, are standard corporate governance practices for executives at large-cap biotechnology firms like Amgen.

Comparison to Industry Standards

• The transaction follows standard executive compensation and tax compliance protocols typical for S&P 500 companies.
• The use of Rule 10b5-1 plans for stock sales is a common practice among pharmaceutical executives to avoid potential conflicts of interest.

Stakeholder Impact

• Minimal impact on shareholders as these transactions are consistent with standard executive compensation programs.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Amgen, AMGN, Insider Trading, Form 4, Equity Incentive Plan, Stock Sale